Muscle health in pulmonary arterial hypertension
Treatments studied
Part of Lungs & breathing clinical trials.
This study looks at how pulmonary arterial hypertension (PAH), a type of high blood pressure in the lungs, affects muscle mass and strength. It aims to find ways to help patients maintain muscle and improve their quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must already be enrolled in the main MUSCLE UP study.
- You must have a diagnosis of pulmonary arterial hypertension (PAH), including certain types such as idiopathic, heritable, drug-induced, or associated with conditions like connective tissue disease, HIV, congenital heart disease, or liver disease.
- Your PAH must have been diagnosed within the last 6 months, or you must have been on a stable treatment for at least 3 months.
- You must have had a right heart catheterization (a test that measures pressure in your heart and lungs) showing specific results.
- You cannot have severe lung disease or significant heart valve problems, and you cannot be pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether using a mobile health tool can help people with pulmonary arterial hypertension (PAH) manage their condition in daily life. It’s aimed at adults who are stable on their PAH medicines and can track activity using a wearable device.
This study tests whether a home-based exercise program, added to your regular medications, can help people who are newly diagnosed with pulmonary arterial hypertension feel better and improve their daily function.
This trial tests a supervised exercise program for people with pulmonary arterial hypertension (PAH), a type of high blood pressure in the lungs. It aims to see if regular exercise can improve your daily function and quality of life.
This trial tests an experimental drug called HS235 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. It aims to see if the drug can help improve symptoms and exercise ability.
This study looks at how your heart and lungs respond to starting a blood vessel–widening medication (a vasodilator) for pulmonary hypertension. It will closely monitor your breathing and heart rhythm to help doctors understand and improve treatment.
This study looks at how exercise affects the lungs, blood vessels, and oxygen use in children with pulmonary arterial hypertension (high blood pressure in the lungs). It compares them to healthy children to understand how the condition impacts the body.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.